A nonclassical vitamin D receptor pathway suppresses renal fibrosis

Ichiaki Ito, Tsuyoshi Waku, Masato Aoki, Rumi Abe, Yu Nagai, Tatsuya Watanabe, Yuka Nakajima, Ichiro Ohkido, Keitaro Yokoyama, Hiroyuki Miyachi, Toshiyuki Shimizu, Akiko Murayama, Hiroyuki Kishimoto, Kazuo Nagasawa, Junn Yanagisawa

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The TGF-β superfamily comprises pleiotropic cytokines that regulate SMAD and non-SMAD signaling. TGF-β-SMAD signal transduction is known to be involved in tissue fibrosis, including renal fibrosis. Here, we found that 1,25-dihydroxyvitamin D3-bound [1,25(OH)2D 3-bound] vitamin D receptor (VDR) specifically inhibits TGF-β-SMAD signal transduction through direct interaction with SMAD3. In mouse models of tissue fibrosis, 1,25(OH)2D3 treatment prevented renal fibrosis through the suppression of TGF-β-SMAD signal transduction. Based on the structure of the VDR-ligand complex, we generated 2 synthetic ligands. These ligands selectively inhibited TGF-β-SMAD signal transduction without activating VDR-mediated transcription and significantly attenuated renal fibrosis in mice. These results indicate that 1,25(OH) 2D3-dependent suppression of TGF-β-SMAD signal transduction is independent of VDR-mediated transcriptional activity. In addition, these ligands did not cause hypercalcemia resulting from stimulation of the transcriptional activity of the VDR. Thus, our study provides a new strategy for generating chemical compounds that specifically inhibit TGF-β-SMAD signal transduction. Since TGF-β-SMAD signal transduction is reportedly involved in several disorders, our results will aid in the development of new drugs that do not cause detectable adverse effects, such as hypercalcemia.

Original languageEnglish (US)
Pages (from-to)4579-4594
Number of pages16
JournalJournal of Clinical Investigation
Volume123
Issue number11
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Fingerprint

Calcitriol Receptors
Signal Transduction
Fibrosis
Kidney
Ligands
Hypercalcemia
Calcitriol
Cytokines
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ito, I., Waku, T., Aoki, M., Abe, R., Nagai, Y., Watanabe, T., ... Yanagisawa, J. (2013). A nonclassical vitamin D receptor pathway suppresses renal fibrosis. Journal of Clinical Investigation, 123(11), 4579-4594. https://doi.org/10.1172/JCI67804

A nonclassical vitamin D receptor pathway suppresses renal fibrosis. / Ito, Ichiaki; Waku, Tsuyoshi; Aoki, Masato; Abe, Rumi; Nagai, Yu; Watanabe, Tatsuya; Nakajima, Yuka; Ohkido, Ichiro; Yokoyama, Keitaro; Miyachi, Hiroyuki; Shimizu, Toshiyuki; Murayama, Akiko; Kishimoto, Hiroyuki; Nagasawa, Kazuo; Yanagisawa, Junn.

In: Journal of Clinical Investigation, Vol. 123, No. 11, 01.11.2013, p. 4579-4594.

Research output: Contribution to journalArticle

Ito, I, Waku, T, Aoki, M, Abe, R, Nagai, Y, Watanabe, T, Nakajima, Y, Ohkido, I, Yokoyama, K, Miyachi, H, Shimizu, T, Murayama, A, Kishimoto, H, Nagasawa, K & Yanagisawa, J 2013, 'A nonclassical vitamin D receptor pathway suppresses renal fibrosis', Journal of Clinical Investigation, vol. 123, no. 11, pp. 4579-4594. https://doi.org/10.1172/JCI67804
Ito, Ichiaki ; Waku, Tsuyoshi ; Aoki, Masato ; Abe, Rumi ; Nagai, Yu ; Watanabe, Tatsuya ; Nakajima, Yuka ; Ohkido, Ichiro ; Yokoyama, Keitaro ; Miyachi, Hiroyuki ; Shimizu, Toshiyuki ; Murayama, Akiko ; Kishimoto, Hiroyuki ; Nagasawa, Kazuo ; Yanagisawa, Junn. / A nonclassical vitamin D receptor pathway suppresses renal fibrosis. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 11. pp. 4579-4594.
@article{60835e0adf1e483c8168f21ea365eb0a,
title = "A nonclassical vitamin D receptor pathway suppresses renal fibrosis",
abstract = "The TGF-β superfamily comprises pleiotropic cytokines that regulate SMAD and non-SMAD signaling. TGF-β-SMAD signal transduction is known to be involved in tissue fibrosis, including renal fibrosis. Here, we found that 1,25-dihydroxyvitamin D3-bound [1,25(OH)2D 3-bound] vitamin D receptor (VDR) specifically inhibits TGF-β-SMAD signal transduction through direct interaction with SMAD3. In mouse models of tissue fibrosis, 1,25(OH)2D3 treatment prevented renal fibrosis through the suppression of TGF-β-SMAD signal transduction. Based on the structure of the VDR-ligand complex, we generated 2 synthetic ligands. These ligands selectively inhibited TGF-β-SMAD signal transduction without activating VDR-mediated transcription and significantly attenuated renal fibrosis in mice. These results indicate that 1,25(OH) 2D3-dependent suppression of TGF-β-SMAD signal transduction is independent of VDR-mediated transcriptional activity. In addition, these ligands did not cause hypercalcemia resulting from stimulation of the transcriptional activity of the VDR. Thus, our study provides a new strategy for generating chemical compounds that specifically inhibit TGF-β-SMAD signal transduction. Since TGF-β-SMAD signal transduction is reportedly involved in several disorders, our results will aid in the development of new drugs that do not cause detectable adverse effects, such as hypercalcemia.",
author = "Ichiaki Ito and Tsuyoshi Waku and Masato Aoki and Rumi Abe and Yu Nagai and Tatsuya Watanabe and Yuka Nakajima and Ichiro Ohkido and Keitaro Yokoyama and Hiroyuki Miyachi and Toshiyuki Shimizu and Akiko Murayama and Hiroyuki Kishimoto and Kazuo Nagasawa and Junn Yanagisawa",
year = "2013",
month = "11",
day = "1",
doi = "10.1172/JCI67804",
language = "English (US)",
volume = "123",
pages = "4579--4594",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - A nonclassical vitamin D receptor pathway suppresses renal fibrosis

AU - Ito, Ichiaki

AU - Waku, Tsuyoshi

AU - Aoki, Masato

AU - Abe, Rumi

AU - Nagai, Yu

AU - Watanabe, Tatsuya

AU - Nakajima, Yuka

AU - Ohkido, Ichiro

AU - Yokoyama, Keitaro

AU - Miyachi, Hiroyuki

AU - Shimizu, Toshiyuki

AU - Murayama, Akiko

AU - Kishimoto, Hiroyuki

AU - Nagasawa, Kazuo

AU - Yanagisawa, Junn

PY - 2013/11/1

Y1 - 2013/11/1

N2 - The TGF-β superfamily comprises pleiotropic cytokines that regulate SMAD and non-SMAD signaling. TGF-β-SMAD signal transduction is known to be involved in tissue fibrosis, including renal fibrosis. Here, we found that 1,25-dihydroxyvitamin D3-bound [1,25(OH)2D 3-bound] vitamin D receptor (VDR) specifically inhibits TGF-β-SMAD signal transduction through direct interaction with SMAD3. In mouse models of tissue fibrosis, 1,25(OH)2D3 treatment prevented renal fibrosis through the suppression of TGF-β-SMAD signal transduction. Based on the structure of the VDR-ligand complex, we generated 2 synthetic ligands. These ligands selectively inhibited TGF-β-SMAD signal transduction without activating VDR-mediated transcription and significantly attenuated renal fibrosis in mice. These results indicate that 1,25(OH) 2D3-dependent suppression of TGF-β-SMAD signal transduction is independent of VDR-mediated transcriptional activity. In addition, these ligands did not cause hypercalcemia resulting from stimulation of the transcriptional activity of the VDR. Thus, our study provides a new strategy for generating chemical compounds that specifically inhibit TGF-β-SMAD signal transduction. Since TGF-β-SMAD signal transduction is reportedly involved in several disorders, our results will aid in the development of new drugs that do not cause detectable adverse effects, such as hypercalcemia.

AB - The TGF-β superfamily comprises pleiotropic cytokines that regulate SMAD and non-SMAD signaling. TGF-β-SMAD signal transduction is known to be involved in tissue fibrosis, including renal fibrosis. Here, we found that 1,25-dihydroxyvitamin D3-bound [1,25(OH)2D 3-bound] vitamin D receptor (VDR) specifically inhibits TGF-β-SMAD signal transduction through direct interaction with SMAD3. In mouse models of tissue fibrosis, 1,25(OH)2D3 treatment prevented renal fibrosis through the suppression of TGF-β-SMAD signal transduction. Based on the structure of the VDR-ligand complex, we generated 2 synthetic ligands. These ligands selectively inhibited TGF-β-SMAD signal transduction without activating VDR-mediated transcription and significantly attenuated renal fibrosis in mice. These results indicate that 1,25(OH) 2D3-dependent suppression of TGF-β-SMAD signal transduction is independent of VDR-mediated transcriptional activity. In addition, these ligands did not cause hypercalcemia resulting from stimulation of the transcriptional activity of the VDR. Thus, our study provides a new strategy for generating chemical compounds that specifically inhibit TGF-β-SMAD signal transduction. Since TGF-β-SMAD signal transduction is reportedly involved in several disorders, our results will aid in the development of new drugs that do not cause detectable adverse effects, such as hypercalcemia.

UR - http://www.scopus.com/inward/record.url?scp=84887459688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887459688&partnerID=8YFLogxK

U2 - 10.1172/JCI67804

DO - 10.1172/JCI67804

M3 - Article

C2 - 24135137

AN - SCOPUS:84887459688

VL - 123

SP - 4579

EP - 4594

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -